Prostate Cancer - Results from #19860

ZYTIGA® plus prednisone demonstrates statistically significant overall survival after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer September 29, 2014

Abiraterone acetate (ZYTIGA®)-development and literature review - Abstract September 29, 2014

Extraprostatic extension of prostatic carcinoma: Is its proximity to surgical margin or Gleason score important? - Abstract September 29, 2014

#ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) September 27, 2014

#ESMO14 - Poster: Long-term cellular response and variables correlating with humoral response in STAND, a randomised phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer September 27, 2014

Bayer and Orion initiate phase III trial of novel prostate cancer agent ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer September 27, 2014

Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer - Abstract September 26, 2014

No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide - Abstract September 26, 2014

Bone complications among prostate cancer survivors: Long-term follow-up from the prostate cancer outcomes study - Abstract September 26, 2014

Identifying suicidal symptoms in prostate cancer survivors using brief self-report - Abstract September 26, 2014

Next-generation prostate-specific antigen test: Precursor form of prostate-specific antigen - Abstract September 26, 2014

A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels - Abstract September 26, 2014

Random variation in rectal position during radiotherapy for prostate cancer is two to three times greater than that predicted from prostate motion - Abstract September 26, 2014

PROVENGE® (sipuleucel-T) demonstrates positive immune responses when sequenced with other therapies in advanced prostate cancer September 26, 2014

Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 Case reports and literature review - Abstract September 26, 2014

Incidence and clinicopathological characteristics of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens - Abstract September 25, 2014

Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients - Abstract September 25, 2014

Cardiovascular risk profile of veteran men beginning androgen deprivation therapy - Abstract September 25, 2014

New era of the treatment of CRPC in Japan - Abstract September 25, 2014

Predicting the Gleason sum of a patient with a prostate biopsy core Gleason ≤ 7 and a prostate biopsy core Gleason ≥ 8 - Abstract September 25, 2014

Page 994 of 1447